open access

Ahead of print
Review paper
Published online: 2022-11-16
Get Citation

Nivolumab in the treatment of thoracic cancer — new possibilities

Magdalena Knetki-Wróblewska1, Kamila Wojas-Krawczyk2
DOI: 10.5603/OCP.2022.0033
Affiliations
  1. Department of Lung Cancer and Chest Tumors, the Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  2. Chair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Poland

open access

Ahead of print
REVIEW ARTICLES
Published online: 2022-11-16

Abstract

Immune checkpoint inhibitors have significantly changed the treatment of patients with advanced non-small cell lung cancer in recent years. The value of nivolumab was initially assessed in patients previously treated with systemic therapy. The association of nivolumab with ipilimumab and the interaction of these antibodies on different immune checkpoints have proven effective in solid tumors (melanoma and renal cell carcinoma). The CheckMate-9LA study assessed the value of dual immunotherapy combined with platinum-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer. A clinical benefit – prolonged overall survival in patients receiving combination therapy – was documented. The results of the CheckMate743 trial for patients with pleural mesothelioma provide a basis for changing the current management algorithm for patients with this diagnosis. Patients diagnosed with mesothelioma of a non-epithelioid type particularly benefit from two-drug immunotherapy compared to chemotherapy. Maintaining the safety of treatment using immunotherapy targeting two immune checkpoints remains the challenge.

Abstract

Immune checkpoint inhibitors have significantly changed the treatment of patients with advanced non-small cell lung cancer in recent years. The value of nivolumab was initially assessed in patients previously treated with systemic therapy. The association of nivolumab with ipilimumab and the interaction of these antibodies on different immune checkpoints have proven effective in solid tumors (melanoma and renal cell carcinoma). The CheckMate-9LA study assessed the value of dual immunotherapy combined with platinum-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer. A clinical benefit – prolonged overall survival in patients receiving combination therapy – was documented. The results of the CheckMate743 trial for patients with pleural mesothelioma provide a basis for changing the current management algorithm for patients with this diagnosis. Patients diagnosed with mesothelioma of a non-epithelioid type particularly benefit from two-drug immunotherapy compared to chemotherapy. Maintaining the safety of treatment using immunotherapy targeting two immune checkpoints remains the challenge.

Get Citation

Keywords

immunotherapy; immune checkpoint inhibitors; nivolumab; non-small cell lung cancer; pleural mesothelioma

About this article
Title

Nivolumab in the treatment of thoracic cancer — new possibilities

Journal

Oncology in Clinical Practice

Issue

Ahead of print

Article type

Review paper

Published online

2022-11-16

Page views

42

Article views/downloads

31

DOI

10.5603/OCP.2022.0033

Keywords

immunotherapy
immune checkpoint inhibitors
nivolumab
non-small cell lung cancer
pleural mesothelioma

Authors

Magdalena Knetki-Wróblewska
Kamila Wojas-Krawczyk

References (30)
  1. Planchard D, Popat S, Kerr K, et al. ESMO Guidelines Committee, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29 Suppl 4(Suppl 4): iv192–iv237.
  2. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2): 123–135.
  3. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627–1639.
  4. Antonia S, Borghaei H, Ramalingam S, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019; 20(10): 1395–1408.
  5. Lind M, Gettinger S, Borghaei H, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Lung Cancer. 2020; 139: S49–S50.
  6. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2): 198–211.
  7. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272): 375–386.
  8. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17): 1974–1982.
  9. Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015; 194(3): 950–959.
  10. Willsmore ZN, Coumbe BGT, Crescioli S, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021; 51(3): 544–556.
  11. Wei SC, Anang NAAS, Sharma R, et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019; 116(45): 22699–22709.
  12. Gide TN, Quek C, Menzies AM, et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019; 35(2): 238–255.e6.
  13. https://www.gov.pl/web/zdrowie/choroby-onkologiczne (23.01.2023).
  14. Reck M, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open. 2021; 6(5): 100273.
  15. Carbone D, Ciuleanu T, Cobo M, et al. First-line nivolumab + ipilimumab + chemotherapy in patients with advanced NSCLC and brain metastases: results from CheckMate 9LA. WCLC 2021.
  16. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2): 198–211.
  17. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. http://onkologia.org.pl/raporty (10.07.2022).
  18. Liu B, van Gerwen M, Bonassi S, et al. International Association for the Study of Lung Cancer Mesothelioma Task Force. Epidemiology of Environmental Exposure and Malignant Mesothelioma. J Thorac Oncol. 2017; 12(7): 1031–1045.
  19. Kindler HL, Ismaila N, Armato SG, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(13): 1343–1373.
  20. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14): 2636–2644.
  21. Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019; 7(7): 569–580.
  22. Zalcman G, Mazieres J, Margery J, et al. French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026): 1405–1414.
  23. Linton A, Pavlakis N, O'Connell R, et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014; 111(9): 1860–1869.
  24. Atanackovic D, Block A, de Weerth A, et al. Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clin Cancer Res. 2004; 10(8): 2600–2608.
  25. Meloni F, Morosini M, Solari N, et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol. 2006; 67(1-2): 1–12.
  26. Tartarone A, Lerose R, Aieta M. Is there a role for immunotherapy in malignant pleural mesothelioma? Med Oncol. 2018; 35(7): 98.
  27. Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulm Med. 2021; 21(1): 148.
  28. Yap T, Nakagawa K, Fujimoto N, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021; 9(6): 613–621.
  29. Okada M, Kijima T, Aoe K, et al. Clinical Efficacy and Safety of Nivolumab: Results of a ulticenter, Opn-label, Single-am, Japanese Phase II study in Malgnant Pleural Mesohelioma (MERIT). Clin Cancer Res. 2019; 25(18): 5485–5492.
  30. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022; 33(5): 488–499.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl